01
Strategic Planning
Portfolio prioritization, competitive positioning, board and investor alignment, and organizational design for execution.
Operator-augmented AI for biopharma strategy
Operator-Led Biopharma Consulting Transforming Vision into Value
We help biopharma companies grow faster and execute better. Most consultants have never run a company. Our Founder, Doug Drysdale, has. He has led 17 acquisitions, raised USD 4B+, and served as CEO of Alvogen and Cybin, among others. That experience is what you get when you work with Katogen. Not a junior team running a framework. An operator who has solved your problem before.
Biopharma consulting
Life sciences advisory built for growth-stage operators
Katogen is an operator-led biopharma consulting firm — not a generalist management consultancy. We provide life sciences advisory when growth-stage and mid-sized companies need judgment on M&A, capital, launch, supply chain, and board-level decisions. Engagements are led by Doug Drysdale and a selective team with decades in the CEO chair. See all consulting capabilities or start a conversation.
Operator judgment
The Katogen Difference
There is a difference between advising on a deal and closing one. Katogen is built on 35 years of building, not just advising. Every recommendation we make is grounded in real decisions, real companies, and real consequences. We have navigated product launches, capital raises, M&A integrations, and board-level crises. We know what works and what fails - because we have lived both.
Capabilities
What We Do
Katogen works across six areas where biopharma companies most often need experienced guidance.
02
M&A, Integration & Capital Raises
Deal thesis through post-close integration; capital structure and raise strategy grounded in 17 transactions and USD 4B+ raised.
03
Novel Therapies & Drug Delivery
Platform diligence, regulatory pathways, and commercial differentiation for novel modalities and delivery technologies.
04
Supply Chain & Operational Scale
CDMO selection, quality systems, API strategy, and scale-up across small-molecule, biologic, and novel formats.
05
Turnaround & Crisis Management
Stabilization, stakeholder alignment, and value recovery when performance or strategy is off track.
06
Fractional Executive & Board Advisory
Interim CEO and C-suite leadership and governance support at inflection points - without a full-time hire.
Leadership
Fractional Executive, Board & Advisory Roles
Not every company needs a full-time hire. Some challenges need an experienced operator for a defined period, then done. Katogen provides fractional C-suite and board-level leadership for growth-stage life sciences companies at critical inflection points.
This works well for companies that are:
- Navigating a major M&A transaction.
- Preparing for a capital raise.
- Managing a company turnaround.
- Building a board ahead of an IPO.
- Filling an interim leadership gap
Context
The Biopharma Landscape
The biopharma sector is under pressure right now. Patent cliffs are accelerating. M&A activity is increasing. Capital markets are tighter than they have been in a decade. Competition is intensifying across every major therapeutic area. Companies that move fast with the right strategy will capture significant value. Companies that move slowly - or with the wrong advice - will not. Katogen exists for the companies that want to move fast and get it right.
Ready To Move From Vision To Value?
If you are navigating a deal, a capital raise, or a growth challenge - let's talk. Engagements are structured as project-based consulting, retained advisory, or fractional executive arrangements. Every engagement starts with a direct conversation with our Founder. No sales team. No junior handoff. Just an operator who has done this before.